Federal Trade Commission v. Neora LLC

CourtDistrict Court, N.D. Texas
DecidedJuly 27, 2020
Docket3:20-cv-01979
StatusUnknown

This text of Federal Trade Commission v. Neora LLC (Federal Trade Commission v. Neora LLC) is published on Counsel Stack Legal Research, covering District Court, N.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Federal Trade Commission v. Neora LLC, (N.D. Tex. 2020).

Opinion

*NOT FOR PUBLICATION*

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

: FEDERAL TRADE COMMISSION, : : Plaintiff, : Civil Action No. 19-19699 (FLW) : v. : : OPINION NEORA, LLC; SIGNUM BIOSCIENCES; : SIGNUM NUTRALOGIX; and JEFFREY : OLSON, : : Defendants. : :

WOLFSON, Chief Judge:

The Federal Trade Commission (“Plaintiff” or the “FTC”) has filed a Complaint alleging that defendants Jeffrey Olson, Neora, LLC (“Neora” or the “Company”) (Olson and Neora collectively, “Defendants”); and Signum Bioscienes; Signum Nutralogix (Signum Biosciences and Signum Nutralogix collectively, “Signum”) violated the Federal Trade Commission Act by, inter alia, operating an illegal pyramid scheme. 1 Before the Court is a motion by Defendants, seeking to dismiss, or transfer this action to the United States District Court for the Northern District of Illinois, where an earlier filed action is pending. In the alternative, Defendants move to transfer this action to the United States District Court for the Northern District of Texas or the United States District Court for the Northern District of Illinois pursuant to 28 U.S.C. §1404(a). For the reasons

1 The FTC settled its claims against Signum prior to filing the instant lawsuit, and filed a Stipulated Order for Permanent Injunction signed by the FTC and Signum, simultaneously with the Complaint in this matter. See ECF No. 1-2, Proposed Order. This Court entered the Stipulated Order for Permanent Injunction on November 15, 2019. See ECF No. 10. Accordingly, the only set forth below, Defendants’ Motion to Transfer, pursuant to Section 1404(a) is GRANTED and this matter is transferred to the United States District Court for the Northern District of Texas. I. FACTUAL BACKGROUND AND PROCEDURAL HISTORY The following facts, as set forth in Plaintiff’s Complaint, are taken as true by this Court on this motion to dismiss.

A. The Defendants and Neora’s Business Model Neora, formerly known as Nerium International, LLC (“Nerium”) is an international multi- level marketing company that sells supplements, skin creams, and other products using a network of “Brand Partners,” (“BPs”) which was founded by defendant Olson in 2011. Compl. ¶ ¶ 9,11,12. Olson has been the Company’s CEO since its inception. Id. at ¶ 11. Neora does business throughout the United States, but it is headquartered and maintains its only corporate office in Farmer’s Branch, Texas. See ECF No. 15, Declaration of Deborah Heisz (“Heisz Decl.”) ¶ 3; Compl. ¶7. Olson is a resident of Fort Lauderdale, Florida. Heisz Decl. ¶ 3; see also Compl. ¶ 9. Since early 2015, Neora has been selling its “Nerium EHT Age-Defying Supplement, Mind

Enhancement Formula” (“Nerium EHT”). Id. at ¶ 13. Nerium EHT’s primary ingredient is eicosanoyl-5- hydroxytryptamide (“EHT”), a supplement which was developed by defendant Signum Biosciences, and its wholly-owned subsidiary, Signum Neutralogix; EHT is licensed exclusively to Neora. Id. at ¶¶ 6, 13. Signum’s principal place of business is purportedly in Monmouth Junction, New Jersey. Id. ¶ 8 In the fall of 2014, Neora and Signum allegedly worked in tandem on a campaign to foster consumer interest in a dietary supplement containing EHT. Id. at ¶ 56. In February 2015, as part of the joint marketing effort with Neora, Signum issued a press release that espoused the potential benefits of EHT. Id. at ¶ 58. Allegedly, Signum emphasized that EHT was discovered “in a partnership between Princeton University and Signum Biosciences.” Id. at ¶ 58. Shortly afterward, in April 2015, Signum and Neora formally announced their partnership and launched Nerium EHT at Nerium’s “GetReal Conference” for BPs in April 2015. Id. at ¶ 61. At the conference, Neora continued to emphasize Princeton University’s purported connection to the development of EHT. Neora’s agents have regularly represented that its supplements can cure, treat, or prevent

concussions, chronic traumatic encephalopathy (“CTE”), Alzheimer’s disease, Parkinson’s disease, and other brain disorders. Id. ¶¶ 13, 51. The FTC challenges the accuracy of Neora’s claims about the health benefits of Neora EHT. Id. at ¶ 69. Furthermore, in the FTC’s view, Neora’s business model renders the company an “illegal pyramid scheme,” because “[Neora’s] compensation scheme emphasizes recruiting new BPs over the sale of products to consumers outside of the organization. [Neora’s] business model makes it unlikely that BPs can earn money by selling product to outside consumers in response to genuine demand.” Id. at ¶ 12. B. The FTC’s Investigation of Neora In June 2016, the FTC began investigating Neora in connection with its belief that Neora’s

business model is, in essence, an illegal pyramid scheme. See ECF No. 16, Declaration of Robert F. Johnson III (“Johnson Decl.”), Ex A, Illinois Action Complaint at ¶ 19. As part of the investigation, the FTC issued a Civil Investigative Demand (“CID”) to Neora, requesting information, documents, and data relating to Neora’s marketing and sale of Neora EHT. Id. at ¶ 20. Thereafter, representatives of the FTC and Neora met in person in Chicago as part of a series of ongoing discussions to reach a resolution. Id. On four occasions, beginning in July 2018, the FTC provided Neora with draft complaints, with captions that indicated that the putative lawsuit was to be venued in the United States District Court for the Northern District of Illinois (NDIL), and threatened an enforcement action. Johnson Decl. ¶ 5, Exs. C-E, G-H. Unrelated to this matter, on August 21, 2019, the United States Court of Appeals for the Seventh Circuit issued its decision in FTC v. Credit Bureau Center, LLC, 937 F.3d 764 (7th Cir. 2019), holding that the FTC could not obtain monetary relief under Section 13(b) of the Federal Trade Commission Act (“FTC Act”). See Johnson Decl., Ex. F., Credit Bureau Center Opinion. It is pursuant to Section 13 of the FTC Act that the FTC has filed the instant enforcement action

here, and seeks to hold Defendants liable in this suit. A few weeks later, on September 6, 2019, the FTC – for the first time -- sent Neora another draft complaint, setting forth this District as the venue for the putative lawsuit, not the Northern District of Illinois. Johnson Decl. ¶ 5, Ex. G. On October 29, 2019, the FTC sent Neora its final draft complaint, which, again, indicated the District of New Jersey as the venue for the action. Johnson Decl. ¶ 5, Ex. H. In its cover letter along with the draft complaint, the FTC explained that the complaint was substantially similar to prior versions and, “[e]arlier today, the Commission unanimously authorized us to file the attached complaint against Nerium, Jeffrey Olson, and Signum, and, separately, the attached settlement with Signum. As we previously suggested, we are

prepared to delay filing the complaint for a short time to give you a final opportunity to settle the entire matter.” See ECF No. 18-1, Declaration of Douglas M. McKenney (“McKenney Decl.”), ¶1, Ex. A. The letter urged that if Neora and Olson were not prepared to “settle the matter, please let us know and we’ll move forward with our filing.” Id. Defendants did not respond to the FTC’s settlement overtures, but rather, initiated a lawsuit in the United States District Court for the Northern District of Illinois (“NDIL”). C. The Illinois Action On November 1, 2019, Neora and Olson filed an action against the FTC in the NDIL seeking declaratory and injunctive relief regarding the legality of the FTC’s threatened litigation (the “Illinois Action”). See generally Johnson Decl., Ex. A, Illinois Action Complaint.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Santiago v. Warminster Township
629 F.3d 121 (Third Circuit, 2010)
Peter Bistrian v. Troy Levi
696 F.3d 352 (Third Circuit, 2012)
Phillips v. County of Allegheny
515 F.3d 224 (Third Circuit, 2008)
Yocham v. Novartis Pharmaceuticals Corp.
565 F. Supp. 2d 554 (D. New Jersey, 2008)
Ricoh Co., Ltd. v. Honeywell, Inc.
817 F. Supp. 473 (D. New Jersey, 1993)
Park Inn International, L.L.C. v. Mody Enterprises, Inc.
105 F. Supp. 2d 370 (D. New Jersey, 2000)
Pittsburgh Logistics Systems, Inc. v. C.R. England, Inc.
669 F. Supp. 2d 613 (W.D. Pennsylvania, 2009)
IMS Health, Inc. v. Vality Technology Inc.
59 F. Supp. 2d 454 (E.D. Pennsylvania, 1999)
Liggett Group Inc. v. R.J. Reynolds Tobacco Co.
102 F. Supp. 2d 518 (D. New Jersey, 2000)
Hoffer v. InfoSpace. Com, Inc.
102 F. Supp. 2d 556 (D. New Jersey, 2000)
Lawrence v. Xerox Corp.
56 F. Supp. 2d 442 (D. New Jersey, 1999)
Calkins v. Dollarland, Inc.
117 F. Supp. 2d 421 (D. New Jersey, 2000)
Tischio v. Bontex, Inc.
16 F. Supp. 2d 511 (D. New Jersey, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
Federal Trade Commission v. Neora LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/federal-trade-commission-v-neora-llc-txnd-2020.